What is Mekonos?
Mekonos is at the forefront of transforming synthetic biology and personalized medicine through its innovative cell and gene technology. Founded in 2017 and headquartered in California, the company is dedicated to developing groundbreaking solutions that address critical needs in healthcare and life sciences. Its work is poised to redefine therapeutic approaches and diagnostic capabilities, positioning Mekonos as a key player in the rapidly evolving biotechnology landscape.
How much funding has Mekonos raised?
Mekonos has raised a total of $29.6M across 2 funding rounds:
Unspecified
$4.6M
Series A
$25M
Unspecified (2020): $4.6M with participation from Elementum Ventures, CRCM Ventures, Good AI Capital, Novartis AG, and HikeVentures
Series A (2021): $25M led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital,
Key Investors in Mekonos
CRCM Ventures
CRCM L.P. is a registered investment adviser based in San Francisco, operating since 2012. The firm provides investment advisory services to clients, focusing on tailored financial strategies. CRCM is registered with the U.S. Securities and Exchange Commission (SEC). Their expertise is aimed at individuals and institutions seeking professional investment management.
Good AI Capital
Good AI Capital is an investment firm dedicated to harnessing the power of artificial intelligence to address significant global challenges. They focus on backing visionary companies in sectors such as Healthcare, Enterprise, and Automation, aiming to generate substantial returns while making a positive impact. The firm offers not only capital but also strategic and operational support, leveraging a strong network of experts to help startups scale effectively. Their mission-driven approach emphasizes the symbiotic relationship between doing well financially and doing good for society.
Reimagined Ventures
Reimagined Ventures is a venture capital firm that invests in visionary entrepreneurs across various industries, including real estate and hospitality. The firm focuses on unique, best-in-class opportunities primarily in the Chicagoland area, aiming to redefine success in hospitality and create memorable experiences. By providing unparalleled flexibility of capital, they support innovative ideas that address persistent challenges. Their portfolio includes transformative projects that range from restaurants to hotels and event spaces.
What's next for Mekonos?
With a recent major strategic investment and a substantial total funding amount of $29.6M, Mekonos is well-positioned for accelerated growth and expanded research and development initiatives. The company's trajectory suggests a focus on scaling its operations, further refining its proprietary technologies, and potentially forging new partnerships to bring its transformative solutions to a wider market. This infusion of capital is expected to fuel innovation and solidify Mekonos's leadership in the cell and gene therapy sector.
See full Mekonos company page
